Year: 2026
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Terrestrial Energy Announces Fourth Quarter and Full Year 2025 Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Written by Customer Service on . Posted in Public Companies.
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
Written by Customer Service on . Posted in Public Companies.
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
Written by Customer Service on . Posted in Public Companies.
Bayport Management Ltd Standalone Financial Statements year ended December 2025
Written by Customer Service on . Posted in Public Companies.
Bayport Management Ltd Group Audited Financial Statements year ended December 2025
Written by Customer Service on . Posted in Public Companies.
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
